Mountain View
biomedical and healthCAre Data Discovery Index Ecosystem
help Advanced Search
Title: Response and Resistance to ER-directed Therapy in ER+ Metastatic Breast Cancer      
ID:
PRJNA369715
description:
Despite the reduction in cancer recurrence and mortality provided by hormonal therapy, estrogen receptor positive (ER+) metastatic breast cancer (MBC) remains the most common cause of breast cancer death, resulting in more than 20,000 deaths in the U.S each year. Although several therapeutic options exist to target the estrogen receptor, resistance to these therapies invariably occurs. Genetic mechanisms of acquired resistance to targeted therapies in ER+ MBC are not well understood. To address this, we developed a prospective biopsy protocol where multiple research biopsies are collected from metastatic samples and used for: pathology; ER/PR/HER2; OncoPanel, a CLIA 300 gene sequencing (seq) panel; whole exome seq (WES); transcriptome seq (RNA-seq); and single-cell RNA-seq (sc-RNA-seq). In some cases, tissue is used for cell line and xenograft generation. Archival primary biopsies are also obtained when possible for parallel genomic studies. Patients are... (for more see dbGaP study page.)
accesstypes:
download
landingpage: http://www.ncbi.nlm.nih.gov/bioproject/PRJNA369715
authentication:
none
authorization:
none
abbreviation:
NCBI
homePage: http://www.ncbi.nlm.nih.gov
ID:
SCR:006472
name:
National Center for Biotechnology Information
homePage: http://www.ncbi.nlm.nih.gov/bioproject
ID:
SCR:004801
name:
NCBI BioProject